MedTrace Logo

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

NCT04295005 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24500

Last updated 2024-08-30

Study results available
· View outcomes & findings →

Summary

Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Empagliflozin

film coated tablet

DRUG

DPP-4i

film coated tablets, specifically Sitagliptin

DRUG

GLP-1-RA

subcutaneous injection or tablet

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-16
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04295005 on ClinicalTrials.gov